突变阳性-话题@MedSci

#突变阳性#

46篇内容 | 611人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1803552, encodeId=341d180355277, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183910, objectId=6dfe18391000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dfe18391000, replyNumber=0, likeNumber=36, createdTime=2020-04-29, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dfe18391000, moduleTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dfe18391000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803554, encodeId=1b21180355452, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=EGFR突变阳性晚期NSCLC一线治疗策略, objectType=article, longId=184327, objectId=4a2618432ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2618432ef2, replyNumber=0, likeNumber=26, createdTime=2020-03-11, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2618432ef2, moduleTitle=EGFR突变阳性晚期NSCLC一线治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a2618432ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803558, encodeId=d3da1803558bd, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=34, createdTime=2021-02-25, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803550, encodeId=b4481803550ec, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, objectType=article, longId=179499, objectId=164d1e9499e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d1e9499e1, replyNumber=0, likeNumber=23, createdTime=2020-01-20, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d1e9499e1, moduleTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=164d1e9499e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803551, encodeId=62391803551cd, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, objectType=article, longId=182628, objectId=4294182628cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4294182628cc, replyNumber=0, likeNumber=42, createdTime=2020-02-21, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4294182628cc, moduleTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4294182628cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803547, encodeId=7a2f180354e0f, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=EGFR突变阳性晚期NSCLC的治疗方案选择, objectType=article, longId=168402, objectId=fee316840246, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fee316840246, replyNumber=0, likeNumber=31, createdTime=2020-03-16, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fee316840246, moduleTitle=EGFR突变阳性晚期NSCLC的治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fee316840246)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803549, encodeId=21401803549f7, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略, objectType=article, longId=178512, objectId=7fb11e8512e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fb11e8512e3, replyNumber=0, likeNumber=30, createdTime=2020-02-26, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb11e8512e3, moduleTitle=【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb11e8512e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803546, encodeId=1f241803546c2, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益, objectType=article, longId=164707, objectId=c304164e0717, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c304164e0717, replyNumber=0, likeNumber=39, createdTime=2020-03-01, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c304164e0717, moduleTitle=奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c304164e0717)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803548, encodeId=6a6c18035488f, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, objectType=article, longId=168762, objectId=f104168e62dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f104168e62dd, replyNumber=0, likeNumber=29, createdTime=2020-05-09, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f104168e62dd, moduleTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f104168e62dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803543, encodeId=7bb8180354364, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, objectType=article, longId=144828, objectId=bdde144828d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdde144828d7, replyNumber=0, likeNumber=36, createdTime=2018-08-31, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdde144828d7, moduleTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdde144828d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803544, encodeId=ba4d18035442e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=NEJM：talazoparib治疗BRCA 1/2突变阳性乳腺癌, objectType=article, longId=146767, objectId=a57b146e67dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a57b146e67dd, replyNumber=0, likeNumber=40, createdTime=2018-09-01, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a57b146e67dd, moduleTitle=NEJM：talazoparib治疗BRCA 1/2突变阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a57b146e67dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803545, encodeId=fb6a1803545ac, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=EGFR突变阳性NSCLC一线治疗持久获益，中位治疗时间达27.6个月, objectType=article, longId=154835, objectId=5ec0154835e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ec0154835e1, replyNumber=0, likeNumber=37, createdTime=2019-09-09, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ec0154835e1, moduleTitle=EGFR突变阳性NSCLC一线治疗持久获益，中位治疗时间达27.6个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ec0154835e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803541, encodeId=a1ba1803541de, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, objectType=article, longId=124734, objectId=05dd124e34e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05dd124e34e0, replyNumber=0, likeNumber=27, createdTime=2018-01-17, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05dd124e34e0, moduleTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05dd124e34e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致, objectType=article, longId=116656, objectId=7181116656ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7181116656ed, replyNumber=0, likeNumber=35, createdTime=2018-09-09, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7181116656ed, moduleTitle=【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7181116656ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803542, encodeId=a7e31803542b5, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著, objectType=article, longId=126225, objectId=afde12622574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afde12622574, replyNumber=0, likeNumber=25, createdTime=2018-04-07, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afde12622574, moduleTitle=NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afde12622574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803538, encodeId=73041803538d6, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, objectType=article, longId=111065, objectId=5e6c111065d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e6c111065d4, replyNumber=0, likeNumber=32, createdTime=2017-11-18, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e6c111065d4, moduleTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6c111065d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803540, encodeId=09d518035408e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, objectType=article, longId=122007, objectId=8d8a12200e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d8a12200e1b, replyNumber=0, likeNumber=41, createdTime=2018-06-12, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d8a12200e1b, moduleTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d8a12200e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803537, encodeId=15a1180353e92, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, objectType=article, longId=108612, objectId=fcb31086129c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb31086129c, replyNumber=0, likeNumber=32, createdTime=2017-09-02, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb31086129c, moduleTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb31086129c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803536, encodeId=c9341803536bd, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=EGFR突变阳性非小细胞肺癌耐药后精准治疗, objectType=article, longId=92666, objectId=34fd926666c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34fd926666c, replyNumber=0, likeNumber=37, createdTime=2018-03-04, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34fd926666c, moduleTitle=EGFR突变阳性非小细胞肺癌耐药后精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34fd926666c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803534, encodeId=c4ef1803534b8, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=2016NICE技术评估指南：cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤（TA414）发布, objectType=article, longId=81114, objectId=c6088111417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6088111417, replyNumber=0, likeNumber=23, createdTime=2017-06-17, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6088111417, moduleTitle=2016NICE技术评估指南：cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤（TA414）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6088111417)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突变阳性

2020-05-29

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**

2020-04-29

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

EGFR突变阳性晚期NSCLC一线治疗策略

2020-03-11

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2021-02-25

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益

2020-01-20

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

EGFR突变阳性晚期NSCLC的全程管理愈发重要

2020-02-21

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

EGFR突变阳性晚期NSCLC的治疗方案选择

2020-03-16

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略

2020-02-26

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益

2020-03-01

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择

2020-05-09

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究

2018-08-31

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

NEJM：talazoparib治疗BRCA 1/2突变阳性乳腺癌

2018-09-01

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

EGFR突变阳性NSCLC一线治疗持久获益，中位治疗时间达27.6个月

2019-09-09

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI

2018-01-17

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致

2018-09-09

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著

2018-04-07

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！

2017-11-18

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述

2018-06-12

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？

2017-09-02

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

EGFR突变阳性非小细胞肺癌耐药后精准治疗

2018-03-04

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

2016NICE技术评估指南：cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤（TA414）发布

2017-06-17

科室
- - 订阅+
  - 更多科室
工具
服务